Hi, Jorj,
ALKS announced a restructuring on 8/26 and is almost back to those levels with nothing changed since. The 60 minute:
siliconinvestor.com
It made up some lost ground on the EOD tape painting and presents a good entry, IMO. Target low $7s in a few days, or about 20%.
AMGN: Kineret, Aranesp going OK, but it paid a lot for Immunex and Enbrel. Can you say expensive indigestion? And that's the fundies, the TA looks intermediate toppy, too. Other bioshorts may work short term on TA, but most of the sector is still oversold, IMO. SCIO a dangerous short into earnings, as there is surprise potential there (see the SI SCIO thread for reasons, it's pretty brief compared to this one). But feel free to short on TA and cover before then.
Disclaimer: though I specialize in biotech, that doesn't mean I'm making the right calls. The above is food for y'all's own thought and action. I have no position in any of 'em in real life -- but seriously might try ALKS and AMGN tomorrow or in the near future if they manage to hold up in the couple of weeks.
Cheers, Tuck |
